Second Cancers Following Radiotherapy in Prostate Cancer Patients in the PLCO
Principal Investigator
Name
Amanda Black
Institution
NCI, DCEG, EBP
Position Title
Staff Scientist
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-18
Initial CDAS Request Approval
Mar 14, 2013
Title
Second Cancers Following Radiotherapy in Prostate Cancer Patients in the PLCO
Summary
An increased risk of second cancers has been observed after radiotherapy (RT) for
the treatment of prostate cancer. The increase in bladder and rectal cancers is likely due to the direct effect of radiation. However, the explanation for an increase in cancers at sites far outside the radiation therapy field, particularly lung cancer, is less clear but may be due to confounding.We plan to examine the association between radiotherapy and second cancers in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial where we can assess the impact of adjusting for potential confounders such as smoking.
the treatment of prostate cancer. The increase in bladder and rectal cancers is likely due to the direct effect of radiation. However, the explanation for an increase in cancers at sites far outside the radiation therapy field, particularly lung cancer, is less clear but may be due to confounding.We plan to examine the association between radiotherapy and second cancers in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial where we can assess the impact of adjusting for potential confounders such as smoking.
Aims
To examine the association between radiotherapy and second cancers in the PLCO Cancer Screening trial adjusting for potential confounders.
Collaborators
Paul F Pinsky, Robert L Grubb, Sarah E Daugherty, Yikyung Park, Lindsay M, Morton, Robert N Hoover, Amy Berrington de González